Guardant Health Inc
guardanthealth.comGuardant Health (NASDAQ: GH) is a precision oncology company that develops and commercializes blood-based genomic tests used to detect and monitor cancer. Revenue comes primarily from clinical test sales to oncologists and cancer centers, with additional revenue from biopharmaceutical partnerships where drug developers use Guardant's sequencing technology in clinical trials. The company's core products include the Guardant360 liquid biopsy test for advanced cancer profiling and the Shield test for colorectal cancer screening in average-risk adults. Guardant competes in the liquid biopsy and cancer screening markets against both established diagnostics companies and molecular testing specialists. The company is headquartered in Redwood City, California and files annually with the SEC as a well-known seasoned issuer. The filing excerpts available do not support disclosure of specific FY2025 revenue figures, segment breakdowns, customer concentration data, or leadership tenure details, so those are omitted.
Products & Services
Guardant360 (advanced cancer genomic profiling), Shield (colorectal cancer screening for average-risk adults), liquid biopsy tests, biopharmaceutical development services.
Revenue Model
Transactional revenue from clinical liquid biopsy test sales to oncologists and health systems, plus biopharmaceutical partnership revenue from drug developers using Guardant's sequencing platform in clinical development programs.
Customers & Markets
Oncologists, cancer treatment centers, health systems, biopharmaceutical companies conducting oncology drug trials, average-risk adults eligible for colorectal cancer screening.
Financial Snapshot
Loading...
